who

Makers of ORSL expand their Rehydration Portfolio – enters Diarrheal Dehydration with Ready-to-Drink WHO ORSMakers of ORSL expand their Rehydration Portfolio – enters Diarrheal Dehydration with Ready-to-Drink WHO ORS

Makers of ORSL expand their Rehydration Portfolio – enters Diarrheal Dehydration with Ready-to-Drink WHO ORS

MUMBAI, India, Jan. 22, 2025 /PRNewswire/ -- Kenvue, the world's largest pure-play consumer health company by revenue and the makers…

3 months ago
New Phase IIIB data shows Novartis Fabhalta improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapyNew Phase IIIB data shows Novartis Fabhalta improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

New Phase IIIB data shows Novartis Fabhalta improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average hemoglobin (Hb) level versus baseline in adult patients…

5 months ago
Show previous Posts